Pathos

Pathos was founded to revolutionize precision medicine in cancer by harnessing the power of machine learning to transform drug development. Pathos aims to accelerate traditional oncology approaches based upon a comprehensive and integrated data-first strategy to discover and develop drugs for precise biological pathways. Pathos is currently pursuing co-development and in-licensing opportunities to build a portfolio of clinical stage oncology assets, applying its technology to find the right patients and indications, resulting in a highly improved probability of success and faster time to market. The founding team built and scaled Tempus Labs, an AI-enabled diagnostics company that has built the world’s largest library of clinical and molecular data and an operating system to make sense of it. Through this experience, the founders have seen how precision medicine can transform lives, yet many patients remain who need better therapies. A new approach is needed to change the paradigm of drug development to rapidly serve these unmet needs, highlighting a unique opportunity for Pathos to pursue. We’re looking for other trailblazers who see the world differently and want to forge this new path with us. While we still operate with the agility of a startup, we are scaling to advance our platform. View More